blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2855500

EP2855500 - METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN(A) EXPRESSION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  07.05.2021
Database last updated on 11.09.2024
FormerThe patent has been granted
Status updated on  29.05.2020
FormerGrant of patent is intended
Status updated on  20.01.2020
FormerExamination is in progress
Status updated on  26.03.2019
FormerGrant of patent is intended
Status updated on  15.11.2018
FormerExamination is in progress
Status updated on  30.10.2018
FormerGrant of patent is intended
Status updated on  18.06.2018
FormerExamination is in progress
Status updated on  07.04.2017
FormerRequest for examination was made
Status updated on  16.12.2016
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010 / US
[2020/27]
Former [2016/07]For all designated states
Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010 / US
Former [2015/15]For all designated states
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010 / US
Inventor(s)01 / CROOKE, Rosanne, M.
2855 Gazelle Ct.
Carlsbad, CA 92010 / US
02 / GRAHAM, Mark, J.
2855 Gazelle Ct.
Carlsbad, CA 92010 / US
03 / FREIER, Susan, M.
2855 Gazelle Ct.
Carlsbad, CA 92010 / US
 [2015/15]
Representative(s)Bieri, Simona Roxana
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2020/27]
Former [2015/15]Chapman, Desmond Mark
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
Application number, filing date13793955.923.05.2013
[2020/27]
WO2013US42532
Priority number, dateUS201261651539P24.05.2012         Original published format: US 201261651539 P
[2015/15]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2013177468
Date:28.11.2013
Language:EN
[2013/48]
Type: A2 Application without search report 
No.:EP2855500
Date:08.04.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 28.11.2013 takes the place of the publication of the European patent application.
[2015/15]
Type: B1 Patent specification 
No.:EP2855500
Date:01.07.2020
Language:EN
[2020/27]
Search report(s)International search report - published on:US30.01.2014
(Supplementary) European search report - dispatched on:EP13.11.2015
ClassificationIPC:C12N15/113
[2015/51]
CPC:
C12N15/113 (EP,IL,RU,US); C07H21/00 (IL,KR,RU); A61K31/7115 (IL,KR,RU);
A61K31/7125 (IL,KR,RU); A61K48/00 (IL,KR,RU); A61P29/00 (EP,IL);
A61P3/00 (EP,IL,RU); A61P39/00 (IL,RU); A61P9/00 (EP,IL,RU);
A61P9/10 (EP,IL,RU); C07H21/02 (IL,KR,RU); C07H21/04 (IL,KR,RU);
C12N15/00 (IL,KR,RU); C12Y304/21007 (EP,IL,RU,US); C12N2310/11 (EP,IL,RU,US);
C12N2310/315 (EP,IL,RU,US); C12N2310/32 (IL,RU,US); C12N2310/321 (IL,US);
C12N2310/3231 (IL,US); C12N2310/3341 (EP,IL,RU,US); C12N2310/34 (IL,US);
C12N2310/341 (IL,US); C12N2310/346 (EP,IL,RU,US); Y02P20/55 (IL,KR) (-)
C-Set:
C12N2310/321, C12N2310/341, C12N2310/3525 (US,EP);
C12N2310/321, C12N2310/3525 (EP,US)
Former IPC [2015/15]C07H21/02, C07H21/04, C12P19/34
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/15]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN ZUR MODULATION DER APOLIPOPROTEIN(A)-EXPRESSION[2015/15]
English:METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN(A) EXPRESSION[2015/15]
French:PROCÉDÉS ET COMPOSITIONS DE MODULATION DE L'EXPRESSION DE L'APOLIPOPROTÉINE(A)[2015/15]
Entry into regional phase18.12.2014National basic fee paid 
18.12.2014Search fee paid 
18.12.2014Designation fee(s) paid 
18.12.2014Examination fee paid 
Examination procedure18.12.2014Examination requested  [2015/15]
13.06.2016Amendment by applicant (claims and/or description)
07.04.2017Despatch of a communication from the examining division (Time limit: M06)
14.11.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
12.01.2018Reply to a communication from the examining division
19.06.2018Communication of intention to grant the patent
29.10.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
16.11.2018Communication of intention to grant the patent
25.03.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
02.04.2019Despatch of a communication from the examining division (Time limit: M04)
01.08.2019Reply to a communication from the examining division
21.01.2020Communication of intention to grant the patent
20.05.2020Fee for grant paid
20.05.2020Fee for publishing/printing paid
20.05.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20180985.2  / EP3822352
EP20212913.6  / EP3825403
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  07.04.2017
Opposition(s)06.04.2021No opposition filed within time limit [2021/23]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
12.01.2018Request for further processing filed
12.01.2018Full payment received (date of receipt of payment)
Request granted
31.01.2018Decision despatched
Fees paidRenewal fee
07.05.2015Renewal fee patent year 03
10.05.2016Renewal fee patent year 04
10.05.2017Renewal fee patent year 05
11.05.2018Renewal fee patent year 06
15.05.2019Renewal fee patent year 07
14.05.2020Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL01.07.2020
MC01.07.2020
MK01.07.2020
RS01.07.2020
SM01.07.2020
[2024/22]
Former [2022/07]AL01.07.2020
MC01.07.2020
RS01.07.2020
SM01.07.2020
Former [2021/25]AL01.07.2020
RS01.07.2020
SM01.07.2020
Former [2021/23]RS01.07.2020
SM01.07.2020
Former [2021/15]RS01.07.2020
Documents cited:Search[IDA]WO2005000201  (ISIS PHARMACEUTICALS INC [US], et al) [ID] 1-13 * the whole document * [A] 14,15;
 [L]WO2013173789  (ISIS PHARMACEUTICALS INC [US]) [L] 1-13 * table 1 *;
 [E]WO2014179625  (ISIS PHARMACEUTICALS INC [US]) [E] 1-15* the whole document *;
 [IDA]  - ESTHER MERKI ET AL, "Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 57, no. 15, doi:10.1016/J.JACC.2010.10.052, ISSN 0735-1097, (20101018), pages 1611 - 1621, (20110226), XP028407468 [ID] 1-13 * the whole document * [A] 14,15

DOI:   http://dx.doi.org/10.1016/j.jacc.2010.10.052
 [A]  - GIUSEPPE LIPPI ET AL, "Antisense therapy in the treatment of hypercholesterolemia", EUROPEAN JOURNAL OF INTERNAL MEDICINE, ELSEVIER, AMSTERDAM, NL, vol. 22, no. 6, doi:10.1016/J.EJIM.2011.06.015, ISSN 0953-6205, (20110629), pages 541 - 546, (20110712), XP028105485 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.ejim.2011.06.015
 [AP]  - MARK GRAHAM ET AL, "Antisense Inhibition of Apolipoprotein(a) in Cynomolgus Monkeys Significantly Reduces Plasma Apolipoprotein(a) Levels Without Affecting Plasminogen or Other Major Lipid Classes", CIRCULATION, (20121103), vol. 126, no. 21, page A11050, XP055226156 [AP] 1-15 * the whole document *
International search[A]WO2010006215  (CELERA CORP [US], et al);
 [A]US2011039910  (CROOKE ROSANNE M [US], et al);
 [A]  - KOORNNEEF, A ET AL., "APOLIPOPROTEIN B KNOCKDOWN BY AAV-DELIVERED SHRNA LOWERS PLASMA CHOLESTEROL IN MICE", MICE. MOL. THER., (20110208), vol. 19, no. 4, pages 731 - 740, XP002732021

DOI:   http://dx.doi.org/10.1038/MT.2011.6
by applicantWO9414226
 WO9839352
 US5877022
 WO9914226
 US6268490
 WO03004602
 WO03014397
 US6525191
 US6670461
 US6770748
 US2004171570
 US6794499
 WO2004106356
 WO2005000201
 WO2005021570
 US2005130923
 US7034133
 US7053207
 WO2007134181
 US2008039618
 US7399845
 WO2008101157
 US7427672
 WO2008150729
 WO2008154401
 WO2009006478
 US2009012281
 US7547684
 US7696345
 US8138328
 WO2013173789
    - KRAFT et al., Eur J Hum Genet, (19960000), vol. 4, no. 2, pages 74 - 87
    - SCHULTZ et al., PLoS One, (20100000), vol. 5, page el4328
    - BERGMARK et al., J Lipid Res, (20080000), vol. 49, pages 2230 - 2239
    - TSIMIKAS et al., Circulation, (20090000), vol. 119, no. 13, pages 1711 - 1719
    - KOSCHINSKY; MARCOVINA, Curr Opin Lipidol, (20040000), vol. 15, pages 167 - 174
    - RIFAI et al., Clin Chem, (20040000), vol. 50, pages 1364 - 1371
    - ERQOU et al., JAMA, (20090000), vol. 302, pages 412 - 423
    - KAMSTRUP et al., Circulation, (20080000), vol. 117, pages 176 - 184
    - CLARKE et al., NEJM, (20090000), vol. 361, pages 2518 - 2528
    - SOLFRIZZI et al., J Neurol Neurosurg Psychiatry, (20020000), vol. 72, pages 732 - 736
    - GRAHAM et al., Circulation, (20120000), vol. 126, no. 21, page 11050
    - MERKI et al., J Am Coll Cardiol, (20110000), vol. 57, pages 1611 - 1621
    - Arch. Int. Med., (19880000), vol. 148, pages 36 - 39
    - FREDRICKSON; LEE, Circulation, (19650000), vol. 31, pages 321 - 327
    - FREDRICKSON et al., New Eng J Med, (19670000), vol. 276, no. 1, pages 34 - 42
    - YUAN et al., CMAJ, (20070000), vol. 176, pages 1113 - 1120
    - JAMA, (20010000), vol. 285, pages 2486 - 2497
    - WOOLF et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, pages 7305 - 7309
    - GAUTSCHI et al., J. Natl. Cancer Inst., (20010300), vol. 93, pages 463 - 471
    - MAHER; DOLNICK, Nuc. Acid. Res., (19880000), vol. 16, pages 3341 - 3358
    - "GENBANK", Database accession no. NM 005577.2
    - "GENBANK", Database accession no. NT 007422.12
    - "GENBANK", Database accession no. NT 025741.15
    - "GENBANK", Database accession no. NM 005577.1
    - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, page 403 410
    - ZHANG; MADDEN, Genome Res., (19970000), vol. 7, page 649 656
    - SMITH; WATERMAN, Adv. Appl. Math., (19810000), vol. 2, page 482 489
    - CHATTOPADHYAYA et al., J. Org. Chem., (20090000), vol. 74, pages 118 - 134
    - SINGH et al., Chem. Commun., (19980000), vol. 4, pages 455 - 456
    - KOSHKIN et al., Tetrahedron, (19980000), vol. 54, pages 3607 - 3630
    - WAHLESTEDT et al., Proc. Natl. Acad. Sci. U. S. A., (20000000), vol. 97, pages 5633 - 5638
    - KUMAR et al., Bioorg. Med. Chem. Lett., (19980000), vol. 8, pages 2219 - 2222
    - SINGH et al., J. Org. Chem., (19980000), vol. 63, pages 10035 - 10039
    - SRIVASTAVA et al., J. Am. Chem. Soc., (20070000), vol. 129, no. 26, pages 8362 - 8379
    - ELAYADI et al., Curr. Opinion Invest. Drugs, (20010000), vol. 2, pages 558 - 561
    - BRAASCH et al., Chem. Biol., (20010000), vol. 8, pages 1 - 7
    - ORUM et al., Curr. Opinion Mol. Ther., (20010000), vol. 3, pages 239 - 243
    - FRIEDEN et al., Nucleic Acids Research, (20030000), vol. 21, pages 6365 - 6372
    - FREIER et al., Nucleic Acids Research, (19970000), vol. 25, no. 22, pages 4429 - 4443
    - ALBAEK et al., J. Org. Chem., (20060000), vol. 71, pages 7731 - 7740
    - BAKER et al., J. Biol. Chem., (19970000), vol. 272, pages 11944 - 12000
    - MARTIN, Helv. Chim. Acta, (19950000), vol. 78, pages 486 - 504
    - ALTMANN et al., Chimia, (19960000), vol. 50, pages 168 - 176
    - ALTMANN et al., Biochem. Soc. Trans., (19960000), vol. 24, pages 630 - 637
    - ALTMANN et al., Nucleosides Nucleotides, (19970000), vol. 16, pages 917 - 926
    - LEUMANN, Bioorg. Med. Chem., (20020000), vol. 10, pages 841 - 854
    - Antisense Research and Applications, CRC Press, (19930000), pages 276 - 278
    - JONES, L.J. et al., Analytical Biochemistry, (19980000), vol. 265, pages 368 - 374
    - LIPPI et al., Clinica Chimica Acta, (20110000), vol. 412, pages 797 - 801
    - FRAZER, K.A. et al., Nat. Genet., (19950000), vol. 9, pages 424 - 431
    - "GENBANK", Database accession no. NT - 007422.12
    - "GENBANK", Database accession no. NT -007422.12
    - "GENBANK", Database accession no. XM 001098061.2
 WO1998DK00393
 US20060086231
 US20060097787
 US20080026995
 US20080026998
 US20080056564
 US20080099844
 US20090989574
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.